SLC16A3 and cancer: The pan-cancer assessment of the prognostic and diagnostic importance of SLC16A3 demonstrated that upregulated expression of SLC16A3 and adverse OS were linked in specific cancers, encompassing BLCA, CHOL, CESC, LGG, LAML, LIHC, LUAD, LUSC, MESO, OSCC, PADD, and UCS (Fig. 4A and L).